Mesothelioma Attorneys
Alfacell Forms New Thoracic Cancer Advisory Board
|
|
BLOOMFIELD, N.J., Jan. 27 /PRNewswire-FirstCall/ – Alfacell Corporation today announced the formation of a Thoracic Cancer Advisory Board to support the Company’s strategic focus on developing novel ribonuclease (RNase) therapies for the treatment of diseases such as mesothelioma and non-small cell lung cancer (NSCLC). The Thoracic Cancer Advisory Board will work in coordination with the Company’s prestigious Scientific Advisory Board, led by Dr. David Sidransky, Director of Head and Neck Cancer Research at Johns Hopkins University, as well as with the Business Policy Committee, chaired by former U.S. Department of Health and Human Services Secretary Tommy G. Thompson. “We are extremely pleased to have attracted such esteemed colleagues to the Alfacell Thoracic Cancer Advisory Board,” stated Kuslima Shogen, Chief Executive Officer of Alfacell. “All are highly-accomplished, internationally-renowned experts in oncology, and are universally recognized as thought leaders and pioneers in mesothelioma and lung cancer research. We look forward to collaborating with Source : accessmylibrary.com |
Related Articles from Attorney for Mesothelioma
NSW court blames Water Board for man’s asbestos poisoning
For close to 30 years, from the '50s to the early '80s, asbestos was used in this country in almost every aspect of industry and building, from brake linings to fibro sheeting. And it's still around -- one in three Australian homes built before 1982 are thought to still contain asbestos. This, despite the known extreme dangers of the stuff and an increasing number of people suffering from mesothelioma -- cancer caused by inhaling asbestos fibres. One of the disease's most worrying characteristics is that it takes decades to develop. Stephen Smith contracted the disease working on a building site in the late 1960s. In
Blood Test May Spot Asbestos-Linked Cancer
A blood test could help screen for pleural mesothelioma, an asbestos-related cancer, a new study shows. The test checks blood levels of a protein called osteopontin. Blood osteopontin levels "rise dramatically" in the early stages of pleural mesothelioma, says researcher Harvey Pass, MD, in a news release. "A rise in the level of this biomarker in workers with past asbestos exposure may indicate to physicians that these people need to be followed even more closely for the development of cancer," he says. Pass is the chief of the division of thoracic surgery and thoracic oncology in the cardiothoracic surgery department at New York University's
Power supply linesman died after asbestos exposure
A father-of-three, who worked with the Electricity Supply Board for over 30-years, died from exposure to asbestos, an inquest heard tonight. Michael Clohessy, 53, from Killcross Lawns, Sandyford in Dublin had worked for the State-owned electricity company as a linesman for 33-years prior to his death on December 6, 2003. His widow, Teresa, told the Dublin City Coroner’s Court: “He did say to the ESB he couldn’t breathe after cutting copper pipes. “He was with the ESB his whole working life.” The family’s solicitor, Peter Duff, said the ESB was Mr Clohessy’s prime employer during his entire lifetime. The court heard that Mr Clohessy, had
Breakthrough on asbestos disease
Doctors are developing the first ever effective treatment for the respiratory disease mesothelioma. Mesothelioma is a disease of the lung lining and chest wall contracted from exposure to asbestos. It is responsible for as many deaths as cervical cancer. The disease has traditionally viewed as untreatable and incurable, but speakers at the British Thoracic Society (BTS) summer meeting in Southampton on Thursday will outline medical and surgical advances that suggest otherwise. They will highlight recent trials which show that chemotherapy treatment improves the symptoms of mesothelioma, while a combination of chemotherapy, radiotherapy and surgery can produce prolonged survival, if the
Statement on malignant mesothelioma in the United Kingdom.
COPYRIGHT 2001 British Medical Association British Thoracic Society Standards of Care Committee Introduction Malignant mesothelioma is one of the more difficult diseases that doctors, patients, and families have to face. It is almost always caused by inhalation of asbestos fibre many years before presentation. Diagnosis can be difficult, there is little hope of a cure, and the disease has the potential for extremely unpleasant symptoms. The incidence is increasing rapidly and the position of mesothelioma in the league table of cancer related deaths is rising. However, few doctors have managed sufficient numbers of patients to have acquired comprehensive clinical experience